Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
Meiji Seika Pharma is looking to file Arcturus Therapeutics’ next-generation mRNA vaccine in Japan in the spring of 2023 with an eye towards summer approval. The drug maker is currently in talks with the US biotech to in-license the vaccine,…
To read the full story
Related Article
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
May 1, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
- Meiji Pharma/KM Biologics Eager to Acquire mRNA Vaccine, Mull Collabs with Upstarts and Academia
July 7, 2022
- mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production
May 31, 2021
BUSINESS
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
- Shionogi’s CEO Pay Up at 302 Million Yen in FY2025
June 22, 2026
- J-TEC Sets Up German Unit to Expand LabCyte Biz in Europe
June 22, 2026
- Daiichi Sankyo CEO’s Pay Rises to 273 Million Yen in FY2025
June 22, 2026
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…